Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

2014390 citationsJournal Articlehybrid Open Access

Authors

Pasireotide LAR demonstrated superior efficacy over octreotide LAR and is a viable new treatment option for acromegaly.

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 99, Issue 3, pp. 791-799

Field-Weighted Citation Impact: 29.39